- May 13, 2022
- 1 min read

NIH Research to Address the Real-Life Challenges of Opioid Crisis

Atlanta, GA | May 2022

https://directorsblog.nih.gov/2022/05/10/rx-and-illicit-drug-summit-a-conversation-on-helping-people-and-families-in-need/

Recent Posts

See All

Clear Scientific Awarded up to $15M from NIDA for Continued Development of Fentanyl Antidote.

Cambridge, MA | Nov 2023 Clear Scientific, a clinical-stage biopharmaceutical company, today announced an award from the National Institute on Drug Abuse (NIDA) of the NIH, with a total potential val

Clear Scientific Awarded $12M NIDA Grant for Continued Development of Meth Antidote.

Cambridge, MA | Nov 2023 Clear Scientific, a clinical-stage biopharmaceutical company, today announced a $12M award from the National Institute on Drug Abuse of the NIH to support development of CS-1

Clear Scientific to Start Phase 1 Trial for Stimulant Antidote.

Cambridge, MA | Oct 2023 Clear Scientific Inc., a Cambridge MA based biopharmaceutical company, announced that the FDA has approved its Investigational New Drug (IND) application for CS-1103, the fir

NIH Research to Address the Real-Life Challenges of Opioid Crisis

Recent Posts

Contact Us